Nyxoah and Alumis Miss Q4 Earnings Estimates Amid Scaling R&D Costs
Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches.